Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVP Robert E. Landry sold 468 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $476.45, for a total value of $222,978.60. Following the completion of the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at $4,335,218.55. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 477.80 on Friday. The company has a market capitalization of $50.66 billion, a P/E ratio of 47.93 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55. The firm has a 50-day moving average price of $487.65 and a 200 day moving average price of $435.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.82 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/27/regeneron-pharmaceuticals-inc-regn-svp-sells-222978-60-in-stock.html.

A number of equities analysts have commented on REGN shares. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price target on the stock. in a research note on Monday, May 15th. Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target on the stock. in a research note on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Credit Suisse Group cut Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price target on the stock. in a research note on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus price target of $495.59.

A number of institutional investors have recently bought and sold shares of REGN. Retirement Systems of Alabama raised its position in Regeneron Pharmaceuticals by 2.6% in the first quarter. Retirement Systems of Alabama now owns 36,757 shares of the biopharmaceutical company’s stock valued at $14,244,000 after buying an additional 927 shares during the period. IFC Holdings Incorporated FL acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $217,000. Korea Investment CORP raised its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. Fisher Asset Management LLC raised its position in Regeneron Pharmaceuticals by 12.7% in the first quarter. Fisher Asset Management LLC now owns 806 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 91 shares during the period. Finally, North Point Portfolio Managers Corp OH acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $11,332,000. 67.16% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.